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Abstract 
The explosive increase in syphilis throughout China and Russia during the past several decades 
represents a global public health threat for several reasons. 1) Most cases are undertreated and thus 
collectively offer optimal conditions for the emergence of resistant strains of the syphilis spirochete, 
Treponema pallidum. No penicillin-resistant strains have been recognized to date, but strains resistant 
to the second line antibiotic agents are now common. 2) The recent discovery of plasmids in T. 
pallidumraises the likelihood of plasmid transfer from other bacteria of various resistance genes, 
especially those directed toward penicillin-type antibiotics, currently the drugs of choice for syphilis. 
3) Compounding the public health threat is the absence of antibiotic successors to penicillin. The 
development new antibiotics would take more than a decade, hence the concern for interim measures 
to treat any emergent multi-resistant strains. Pre-antibiotic treatment of syphilis involved two 
mechanisms -- 1) agents which are directly toxic to T. pallidum, such as heavy metals and 2) fever 
induction in patients which reduces spirochetal survival, such as malariotherapy and bacterial 
pyrogens. The appearance of multi-drug resistant strains of syphilis in the absence of effective 
antibiotic therapy may require reviving and improving upon treatments used previously. 
Keywords: syphilis; on-antibiotic therapy; resistant strains; plasmids; fever therapy; penicillin 
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Introduction 
 
There are three reasons for interest in the therapies of syphilis before antibiotics. The first is the 
recent explosive increase in this disease worldwide. The second is the risk of strains emerging 
which are resistant to all current anti-syphilis antibiotics -- especially to penicillin and penicillin-
related agents, the drugs of choice for syphilis currently. The third reason is the lack of new 
antibiotics to succeed the penicillin’s. Therefore, past therapies for syphilis (with modern 
improvements) may offer potential alternatives in the absence of effective successor antibiotics. 
 
In the US after the advent of penicillin in the mid-1940s, the incidence of syphilis fell to 
2.1/100,000 by 2000 [1]. But in 2013, the incidence tripled -- to 5.5/100,000 in the population at 
large and 9.3/100,000 in men, presumably due to increased male homosexual infections [2]. 
Elsewhere in the world there has been an ‘explosiveresurgence’ of syphilis with levels of 
32/100,000 in China at large and 77/100,000 in Shanghai in 2008 [3]. The most recent published 
figures for Russia date only to 1996, when the incidence had risen to 263/1000 throughout the 
country and 318/100,000 in St.Petersburg [4]. The economic, political, and social conditions 
accounting for these increases are discussed elsewhere [5]. Data on the overall prevalence of 
syphilis in India, Indonesia, South America, Africa, and other developing countries are not 
readily available, but the incidence has likely risen there also. 
 
2. The Potential Development of Multiple Resistant Strains of T. pallidum 
 
The optimal drug for treating syphilis is penicillin or one of its derivatives -- all containing a 
crucial but vulnerable β-lactam ring. Bacterial strains resistant to penicillin possess the enzyme 
β-lactamase, which disables the β-lactam ring. No penicillin-resistant strains of T. pallidum have 
yet been reported, but they seem inevitable from a genetic perspective, as explained later. 
Persons allergic to penicillin are treated with second-line antibiotics -- e.g., macroides 
(azithromycin, erythromycin, spiramycin) and tetracyclines (doxycycline, etc.) [6]. Strains of T. 
pallidum resistant to these second-line antibiotics have appeared. For example, azithromycin 
resistance was found in 77.3% ofthe T. pallidum specimens isolated in San Francisco during 
2006 [7]. 
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The issue at hand is whether strains may emerge resistant to both penicillin-type drugs and the 
second-line antibiotics. Each syphilitic is a human incubator harboring in his/her gut and 
elsewhere a vast array of organisms which interact with one another and transfer genetic 
information among them via plasmids. 
 
These are small pieces of DNA containing genes, some of which may code for a specific 
antibiotic resistance. For example, strains of Neisseria gonorrhoeae acquired resistance to 
penicillin via plasmids encoding β-lactamase activity, which came fromampicillin-
resistantstrains of Haemophilus influenzae [8]. 
 
The discovery in 1981 that plasmid DNA exists in T. pallidum indicated that it has the potential 
to acquire resistance to penicillin by genetic mechanisms frequently used by other bacteria 
[9,10]. Another example of plasmid transfer involves a strain of Klebsiella pneumoniae -- an 
enteric organism. It produces an enzyme which breaks down carbapenem -- a β-lactam antibiotic 
like penicillin G. This enzyme is coded by a plasmid and can move from K. pneumoniae to other 
bacteria -- e.g., to T. pallidum. The potential for such a transfer represents “a risk as serious as 
terrorism” [11]. A major therapeutic threat to the world would be strains of T. pallidum 
expressing multiple resistance --i.e., to all forms of penicillin and backup agents. There are 
numerous examples of such multiple resistances in other bacteria -- i.e., in staphylococci, enteric 
bacilli, Mycobacterium tuberculosis, etc. Antibiotic resistance is regarded as the greatest current 
threat to global public health [12]. 
 
The most of the 36 million-plus people infected with T. pallidum are untreated and collectively 
represent a global incubator capable of spreading this infectious disease to others throughout the 
world. A strain of T. pallidum resistant to all available anti-syphilis antibiotics may ultimately 
appear somewhere and spread into the US population via international travel and human sexual 
promiscuity. The emergence of an epidemic of untreatable syphilis would elicit a search for new 
anti-syphilitic drugs, but there is little urgency to do so in advance of the need. 
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3. The Present Therapeutic Void: No New Anti-syphilis Antibiotics 
 
Public health officials are concerned that the ‘developmental pipeline’ for new antibiotic agents 
‘is empty’ because many pharmaceutical companies found this area unprofitable, focusing 
instead on drugs treating common chronic diseases. 
 
Roche “fled the field in 1999.” Eli Lilly “dropped its antibiotic research in 2002,” and other 
companies joined them in abandoning the area [13]. The fear of drug-resistant bacteria has 
prompted the US government “to coax companies back to the field,” but the expertise and 
momentum they once had may take years to regain. 
Based on studies by J.A. DiMasi and others, developing a drug from its discovery through 
clinical trials and final federal approval takes “more than ten years” [14,15]. Another paper 
estimated 23 years from “start of development” to “profit” [13]. This concern prompted a recent 
article entitled as a question --“A return to thepre-antimicrobial era? [16]. 
 
4. Recent Exploitation of Old ‘Cures’ for Other Infections 
 
An example of an ancient cure being used today is the recent report of “A 1000-Year Old 
Antimicrobial Remedy with Antistaphylococcal Activity” [17]. It involved a specially prepared 
mixture of garlic, onion, and ox gall, which proved effective against the biofilm of methicillin-
resistant S. aureus. This remedy was found in an Anglo-Saxon manuscript (a leech book in the 
British Museum) describing a cure for an eye infection. Another example of a therapy 
resurrected from the past is the 2015 Nobel Prize in Medicine awarded to YouYou Tu for 
determining the active component of an ancient Chinese herbal medicine which is highly 
effective against the malaria parasite. Arteminin has been isolated from the wormwood plant 
(Artemisia annua) [18]. Like the above recipe found in a medieval medical handbook or the 
ancient Chinese herbal cure, the pre-penicillin treatments of syphilis warrant study. A modern 
assessment of some past ‘cures‘ might suggest a potential, non-antibiotic therapy for a multi-
drug resistant luetic infection. 
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The pre-antibiotic treatments of syphilis had an empirical beginning. Early in the 500-year long 
history of treating syphilis, physicians exploited clinical experiences with patients having skin 
conditions like that of this disease and were also influenced by prevalent folk notions about 
infectious diseases. With the newer knowledge of microbiology and immunology, more rational 
therapies were pursued later. This history becomes apparent when past treatments are surveyed 
chronologically as they appeared. 
 
 
5. Syphilis Treated with Mercury 
 
According to early medical accounts, the first cases of syphilis occurred in medieval Spain and 
Italy and presented with horrendous skin lesions erupting within several weeks of acquiring the 
infection.Many of its original names reflected the initial clinical presentation:pustula mala, 
morbo serpentine, pestilentiali scorra (decay), las buvilla (pustules), bubas (Spanish for bubo), 
the great pox (in contrast to smallpox). Fig.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Head of a young man with secondary syphilisby Hans Holbein, the Younger. 
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Foul smelling, purulent lesions were frequently followed by swollen gummatous bone lesions 
and often by a painful death. The ‘bad legge’ of Henry VIII (1491-1547) was a gumma -- 
syphilitic periostitis of the tibia [19]. 
 
The most widely read, early description of syphilis was that published in 1519 by Ulrich von 
Hutten (1488-1523), a German poet and satirist, who had contracted syphilis. He described 
“Boils that stood out like Acorns, from whence issued such filthy stinking Matter … the Colour 
of these was of a dark Green … the pain itself … was as if the Sick had lain upon a fire” [20]. 
Hutten complained of multiple bone lesions -- a flux at the top of his head, a draining sore under 
the last rib, a foul, painful ulcer in the middle of one tibia, and another above his right heel 
causing unbearable pain upon walking [21]. 
 
These offensive skin lesions and other manifestations of venereal syphilis were treated with 
mercury administered by one of three routes. Ointments containing mercury (unguentum 
Saracenicum) were described in a 1498 treatise by a doctor in the Spanish court [22]. Long 
before him, Arabist physicians (those writing in Arabic, including Persians and Jews) treated 
leprosy, eczema, and other skin afflictions with mercury inunctions [23]. These salves were 
introduced to Western Europe by the returning crusaders and medieval scholars who translated 
Arabic medical texts into Latin. A second form of mercurial treatment emerged from the efforts 
of Middle Eastern and European alchemists to make gold by firing various ores in furnaces. 
 
They knew that heating cinnabar (HgS) releases elemental mercury into the air and probably 
suspected that this heavy metal was absorbed into their exposed skin. Doctors exploited this 
suspicion. Several sixteenth-century woodcuts depict an infected person sitting inside a round 
oven-like chamber over pans of cinnabar being heated at his feet. 
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Fig. 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
Fig. 2. Cinnabar oven for treating syphilitics by exposing them to mercury vapors. 
 
 
A third route for mercury, per os, was promoted by Paracelsus (1493?-1541), a Swiss-German 
alchemist and physician, who prescribed pills of calomel (mercurous chloride, HgCl). The 
presumed curative dose of mercury in any form or route is dangerously close to a toxic level 
[24]. Over a long period, the absorption of too much mercury leads to ulcerations of the lips, 
tongue, palate and jaw with a resulting fetid breath, excessive salivation, and loss of teeth. The 
end-point in mercury therapy for syphilis was originally judged to be a copious secretion of 
saliva -- “some few liters per diem” [25]. It was reasoned that pituita, the body humor 
presumably causing the symptoms and signs of syphilis, was in excess and could be expelled via 
saliva. But this therapeutic complication was later avoided by using instead botanical agents 
newly discovered in the West Indies and imported from there and the Far East. 
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6. Guaiacum and Other Botanical Agents 
 
A common medieval notion held that the cure for a disease could be found in the land where it 
originated. Syphilis has been thought to have been brought into Europe by Columbus’ sailors 
infected while in the West Indies. When it was first learned that natives there used an extract of 
bark from the local guaiacum tree to treat skin lesions, this seemed a possible source of medicine 
for healing syphilis in Europeans. Guaiacumofficinale is an evergreen which reaches thirty or so 
feet high and has leaves like those of the arbutus tree. According to several sixteenth-century 
authors, this botanical treatment came to Spain around 1508 or 1517 [26]. An early woodcut 
shows a man chopping wood fragments from the log of a guaiacum tree, a woman boiling them 
to extract the active agent, and a doctor administering the potion to a patient in bed. Fig.3. 
Footnote 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Preparing a decoction from Guaiacum wood 
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A short-lived rival to guaiacum was China root (Smilax sinensis). This was imported into Europe 
around 1535 from the Far East among various new herbs and spices – cinnamon, cloves, ginger, 
and nutmeg. All were examined for potential medicinal properties. Locally grown rhubarb 
(Rhaponticumrheponticum) was also tried in treating syphilis. Andreas Vesalius (1514-1564), the 
Belgium anatomist, during his later career became prominent as physician to Emperor Charles V 
of the Holy Roman Empire and received frequent requests for medical advice from European 
doctors. His response to an inquiry about treatment for syphilis with China root was contained in 
a long letter later published as the China Root Epistle, 1546. He seemed skeptical of its medical 
value and later declared that “a China root decoction is far inferior to a guaiacum extract” [27]. 
Another new agent imported from China was sarsaparilla (Sassafrasizumu), which Vesalius 
penned as Spartam parillam. However, he recommended using familiar, local herbals “rather 
than those foreign roots and stumps [sold to us] so dearly” [27]. Here he had in mind locally 
grown rhubarb (Rhaponticum rheponticum). Footnote 2. 
 
7. Malarial Fever Therapy 
 
When a syphilitic was given guaiacum (or one of the above agents) in place of mercury, toxic 
symptoms of the heavy metal generally subsided and the person soon felt better. Some aspect of 
the body’s natural reparative functions may have contributed (see below), but the credit for the 
lessened symptoms was often given to the botanical. However, by the seventeenth century 
guaiacum was no longer considered a reliable cure for syphilis, although it was recommended by 
several notable eighteenth century physicians– Hermann Boerhaave (1668-1738) and Jean 
Astruc (1684-1766). 
 
There is another explanation for syphilitics feeling better when mercury therapy was replaced by 
a botanical-- namely, the febrile response produced by the new therapy of guaiacum, China root, 
or sarsaparilla. All three are sudorific – i.e., produce sweating “with warmth in the stomach” 
[26]. Indeed, four centuries later, fever therapy became the prescribed therapy for neurosyphilis, 
as discussed shortly. 
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But first, of anecdotal interest here are the circumstances surrounding the cure of syphilis 
claimed by Benvenu to Cellini (1500-1571), a Florentine goldsmith and favorite of several 
popes. He had acquired syphilis “from the fine young servant-girl [he] was keeping” and claimed 
that “taking the wood” (guaiacum) cured him. However, near in time to this remission, he had 
gone shooting in the marshy campagna near Rome, where he contracted malaria [28]. Paul 
Luttinger speculated that malarial fever may have relieved the symptoms and signs of his 
syphilitic infection [29]. 
 
In the late 1800s, Julius Wagner von Jauregg (1857-1940), a Viennese neurologist and 
psychiatrist, had become interested in the impact of fever on psychoses when he saw an 
institutionalized female patient who had contracted erysipelas and who soon recovered from a 
severe mental illness which may have been tertiary syphilis. In the medical literature Wagner-
Jauregg discovered other case reports of psychotic patients who improved after becoming 
infected with typhoid, typhus, intermittent fever, recurrent fever, erysipelas, or others diseases 
[30]. At the time it was expected that many persons with syphilis would develop symptoms and 
signs of general paresis (paralysis).Wagner-Jauregg found that Austrian army officers with 
syphilis did not become paretic if they had also contracted malaria or relapsing fever [31]. So 
convinced did he become of the benefit of fever in neurosyphilis that he initiated clinical trials of 
his own. He induced fever in syphilitics with tuberculin (1-10 mg) and observed in many the 
remissions their neuropsychiatric symptoms and signs. Injections of Old Tuberculin induce a low 
grade fever lasting 18-36 hours in those who have had active or latent tuberculosis, which 
included over 1/7
th
 of Europeans of that period [32,33,34]. But Jauregg’s most publicized 
therapeutic experiment involved injecting neurosyphilitics with a mild form of malaria 
(Plasmodium vivax), a fever-inducing parasitic infection which could be suppressed with 
quinine. 
 
Other physicians soon began using malariotherapy in uncontrolled studies of neurosyphilitics 
and reported clinical success rates of 33% to 51% and only a 5% mortality [35]. Persons with 
tabes dorsalis (the ‘wasting’ paralysis of neurosyphilis) were hospitalization for three-weeks of 
Alter nate-day fever therapy involving five-hour long hot baths and extended periods wrapped in 
heavy blankets.  
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In other such syphilitics, fever was induced with intravenous injections of malarial blood or a 
bacterial vaccine. Malaria therapy entailed injections of 2-10 cc of whole blood taken from a 
person with tertian malaria. 
 
The subjects experienced 12-16 chills over that many days before the infection was terminated 
with quinine [36]. A 1931 medical text summarizes in a table 35 studies involving 2356 cases of 
general paresis treated with malaria and reported a 27.5% “full remission” [37]. The bacterial 
vaccine treatment involved a course of 18 to 23 injections of a killed typhoid organisms 
administered every second or third day and sufficient to produce a fever of 103
o
 to 104
o
F [38]. 
This protocol was often repeated two months later. Clinical fever therapy gained experimental 
support from laboratory studies on the thermal lability of T. pallidum. This spirochete does not 
grow readily in regular bacterial cultures but can be propagated in the testes of infected rabbits, 
maintained in suspensions for exposure to various experimental conditions, and then tested for 
viability/infectivity by injection into other rabbits. Schamberg reported that rabbits given 
syphilitic inoculations did not become infected if then subjected to a hot bath of 45
o
C [113
o
F] 
for fifteen minutes on eleven consecutive days [39]. Weichbrodt and Jahnel also infected rabbits 
with syphilis and reported that spirochetes in their chancres disappeared and scrotal syphilis was 
cured when the animals were promptly kept at a temperature of 42
o
-44
o
C for thirty minutes. 
Exposure to the higher temperature for a longer period was often fatal [40]. The human body can 
safely withstand a fever of 41.5
o
C to 41.7
o
C for five hours, but a temperature of 42.
o
C (107.6
o
F) 
is dangerous for more than a short period [41]. 
 
Recall that 16
th
 century syphilitics who were subject to mercury fumigation in oven-like 
chambers endured severe sweating conditions. Some died during the treatment. But for others 
who survived, the prolonged elevated body temperature may have ‘produced a cure’. In 
summary, fever was the common therapeutic denominator in the cinnabar-oven treatment, 
botanical sudorifics (guaiacum, China root), malarial infections (natural and iatrogenic), and 
bacterial (tuberculin) vaccine therapy. 
 
 
 
Nessa Publishers|www.nessapublishers.com Page 12 
 
Journal of Infectious Diseases and Immunology Volume 1| Issue 1 
 
 
 
8. More on Mercury and Other Metals 
 
In the mid-nineteenth century, physicians resumed using salts of mercury as a treatment for 
syphilis, which was given then by parenteral routes. In the 1860s Guiseppe Profeta (1840-1910) 
injected luetics with calomel (mercurous chloride, HgCl) [31]. The bichloride form (HgCl2) was 
later given intramuscularly by Berkeley Hill (1834-1892), University College in London and by 
G. R. Lewin (1820-1896), Charité Hospital in Berlin [42]. During and after the First World War, 
mercury oxycyanide and colloidal mercury sulphide were administered intravenously [43]. But 
none of these produced convincing cures. 
 
Besides mercury, Paracelsus had also promoted the clinical use of various other metals, such as 
arsenic, antimony, bismuth, copper, and iron. In 1863 arsenic acid was chemically linked to the 
dye aniline (aminobenzene) by a French professor of medicine and pharmacy, P-J-A. Béchamp 
(1816-1908), who tested the complex on luetics. More familiar is the work of the German 
bacteriologist/immunologist Paul Ehrlich (1854-1915) with atoxyl (sodium arsenilate), which 
had first been used in treating trypanosomiasis and only later syphilis. But atoxyl injures the 
optic nerve, causing blindness. This prompted Ehrlich to synthesize and test many other related 
organic arsenicals, of which two proved safe to use -- arsphenamine (Compound 606) and later 
neoarsphenamine (Compound 914). 
 
In the early twentieth century, the injection of bismuth salts was also introduced in the treatment 
of syphilitics. In 1919, Wilhelm Kolle (1868-1935) reported that a rabbit retaining a deposit (“a 
plug”) of bismuth in one ear was resistant to infection by an inoculums of the spirochete. The 
animal became susceptible to chancre formation once the plug was excised, suggesting the 
prophylactic value of a chronic, slow release of this metal into the circulation [43]. In the 1930s, 
one treatment schedule for luetics included three intramuscular injections sequentially over a six-
week period of arsphenamine, a bismuth salt, and a mercury compound. Evidence of this 
treatment persisted in the patient’s buttock indefinitely, since the heavy metals (Hg, Bi) remained 
visible as radiopaque spots on fluoroscopy or X-rays of the lower abdomen. 
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During the decades before the advent of penicillin in the mid-1940s, the clinical management of 
syphilitics was the specialty of dermatologists, who spent “from one fifth to one third” of their 
efforts on this one disease. Each touted his own treatment protocols. One author covered Modern 
Clinical Syphilology in 1326 pages exclusive of the indices [43]. 
 
Apart from the trio of IM injections noted above, many other regimens were employed. For 
treating early syphilis, Harry Beckman gave intramuscular injections of arsphenamine 
(Salvarsan, Compound 606), mercury by inunctions, and oral potassium iodide [37]. In the 
treatment of early syphilis J.H Stokes and V.C. Garner administered 20-40 injections of 
arsphenamine in combination with bismuth. A British venerologist recommended 14 weekly 
injection of neoarphenamine with bismuth [43]. Another suggested Compound 914 and bismuth 
followed by iodides for two weeks. Five US syphilis clinics pooled their patient data in the 1930s 
and found a 6.5% cure rate based on physical examination and negative serologies after a six 
month observation period [43]. 
 
9. Iodine 
 
In the early 1800s, potassium iodide was introduced for treating luetics. This therapy stemmed 
indirectly from the age-old remedy for goiter. The ashes of sea weeds and burnt sponge had been 
prescribed by Roger of Palermo (fl. 1210 AD) for relieving bronchocele (goiter).It was from the 
ashes of kelp that iodine was isolated in 1811 by a French chemist, Bernard Courtois (1777-
1838) [44]. In 1819, J-F. Coindet (1774-1834) of Geneva began administering potassium iodide 
to goitrous patients. Because their bronchoceles shrunk in size, he speculated that iodine may 
cause general absorption of fibrous tissues of other diseases [45,46]. Such tissues in syphilitics 
include gummas, which are masses of epithelioid and giant cells surrounded by fibroblasts and 
infiltrated with capillaries, lymphoid cells, and infectious spirochetes. Favorable clinical results 
were reported from Dublin and Paris. Syphilitics also reported general relief after bathing in the 
warm iodine springs at Halle, Austria [47,48].  
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In 1831, Robert Williams, a professor of chemistry at the Royal College of Surgeons, advocated 
treating luetics with potassium iodide, expecting an effect on their gummatous lesions [47]. 
Favorable results from administering KI were reported in 1836 by William Wallace (1791-1837) 
of Dublin and confirmed by Philippe Record of Paris [48].  
 
However, iodides have “no [direct] spirillicidal action” [43]. It was suggested that they might 
render gummatous lesions more penetrable by potent antisyphilitic agents [37,43]. In any cases, 
the supposed beneficial effects prompted the admonition, “When one doesn’t know the how and 
why, then one gives iodine” (Wenn man nicht weissWieso und Warum, Dann gibt man 
Jodkalium) [49]. The above notion of enhancingpenetration explains why many later 
syphilologists included iodide along with arsphenamine and heavy metals (Stokes 1934). 
 
10. Penicillin and Other Antibiotics 
 
In 1928, Alexander Fleming (1881-1955) observed lysis of bacterial colonies growing on a 
nutrient agar plate which had become contaminated with Penicillium notatum. The mold released 
a factor into culture medium which inhibited the growth of many common pathogenic bacteria. 
A decade later Howard Walter Florey (1898-1968) and Ernst Boris Chain (1906-1979) isolated 
penicillin and showed in animal experiments that it cured various bacterial infections while being 
non-toxic to the host. During the early 1940s, production of penicillin was begun at Oxford and 
soon developed on an industrial scale in the United States. Later studies showed that penicillin 
was the most effective chemotherapeutic then known against pus-forming cocci, many bacilli, 
and the treponemes [50]. Penicillin approximated the magic bullet (the therapia 
sterilisansmagna) sought previously by Ehrlich for syphilis. Three classic papers 
demonstratingits clinical effectiveness against this disease were published together in 1994 
[51,52, 53]. 
 
11. An Additional Concern 
 
Apart from the threat of penicillin-resistant strains of T. pallidum emerging, a remote worry is 
whether virulent strains could appear producing the horrendous clinical states and early deaths 
reported when venereal syphilis occurred in Europe during the several the decades after 
Columbus’ first voyage. 
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An epidemiological explanation for this initial picture is that the population then had little or no 
natural/herd immunity to this newly imported disease. It is difficult to judge herd immunity to 
syphilis in present day populations. 
 
R.J. Knell suggested that in the early 1500s those syphilitics with grossly repulsive skin lesions 
had fewer sexual encounters for transmitting the Columbian strain, which then faded from the 
population leaving the milder endemic European strain [54]. If this was the explanation, then 
such a highly virulent treponemal strain might one day spontaneously reappear as it did in 
Columbus’ time but perhaps would be replaced ultimately with a less offensive strain by the 
social selection of sexual partners. 
 
12. Conclusions 
 
As noted earlier, while T. pallidum strains resistant to second-tier antibiotics now exist, no 
penicillin-resistantstrains of T. pallidum have yet been reported [6,55]. But their eventual clinical 
appearance seems inevitable. Their presence would be suggested if an acutely infected person 
did not respond clinically to penicillin therapy. Such resistant strains may already exist 
somewhere in the millions of untreated syphilitics but could only be verified by expensive 
laboratory/rabbit studies. 
 
The early treatments of syphilis might be considered if ever strains of T.pallidumresistant to both 
penicillin and the back-up agents are recovered from a patient.Fever treatment (malariotherapy) 
was effective in relieving the signs and symptoms in many persons with neurosyphilis in the 
past, presumably because of the sensitivity of T. pallidum to high body temperatures. While 
syphilis therapeutics has been wedded to the concept of a ‘magic bullet’ killing the infecting 
spirochetes (einemagische Kugel), the other important consideration in this disease process is the 
host. Also to be exploited is the protection offered by the host’s immune response in the form of 
vaccines, a subject treated elsewhere [5].  
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FOOTNOTE 1. An early recommendation for guaiacum was presented in the 1519 book by 
Ulrich von Hutten. He received eleven courses of mercury with only painful results but later 
claimed a total cure after taking guaiacum for two years. However, his condition relapsed four 
years later, and he died at age thirty-five [26]. 
 
His medical story was read by Girolamo Fracastoro (1478/83-1553), an Italian physician, who 
was prompted to amend a poem he had composed by adding a third part about guaiacum. It 
related the story of a shepherd named Syphilus, who had contracted the loathsome skin disease 
but was cured with the botanical -- hence the disease’s later common name ‘syphilis'. 
 
FOOTNOTE 2. In De contagion (1546), a treatise describing epidemics of his period, 
Fracastoriohad written that it “is characteristic of doctors to be always introducing novelties 
[new agents], since they thus acquire greater authority and make more money” [56]. 
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